Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Press Barbados.
Press releases published on July 30, 2025
Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference
GlobeNewswire
·
July 30, 2025
HOUSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid …
BioNexus Gene Lab Corp. and Fidelion Diagnostics Announce Landmark Alliance—Touted as a new “DeepSeek Moment” in Precision Oncology
GlobeNewswire
·
July 30, 2025
KUALA LUMPUR, Malaysia, July 30, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (“BGLC”, Nasdaq: BGLC) and Fidelion Diagnostics Pte Ltd, a Singaporean company (“Fidelion”) today announced the signing of a term sheet for a strategic, cross-equity …
BrainsWay to Report Second Quarter 2025 Financial Results on August 13, 2025
GlobeNewswire
·
July 30, 2025
BURLINGTON, Mass. and JERUSALEM, July 30, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ …
MIMEDX Announces Strategic Collaboration with Vaporox, Inc.
GlobeNewswire
·
July 30, 2025
MARIETTA, Ga., July 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) and Vaporox, Inc. (“Vaporox”) today jointly announced a collaboration, whereby the companies will co-promote and co-market their wound care …
PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025
GlobeNewswire
·
July 30, 2025
PETACH TIKVA, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its second quarter 2025 financial …
Incannex Reports Positive Topline Results from RePOSA Phase 2 Trial of IHL-42X
GlobeNewswire
·
July 30, 2025
Statistically and clinically significant improvements across key clinical endpoints; IHL-42X reduced AHI by up to 83% from baseline. IHL-42X demonstrates compelling clinical benefit and an outstanding safety profile that exceeded expectations. NEW YORK and …
Kane Biotech Showcases revyve™ Preclinical and Clinical Case Study Findings at North American Wound Care Conferences
GlobeNewswire
·
July 30, 2025
Clinical case series showed clinically meaningful reductions in wound size and pain, and improved tissue regranulation in chronic wound patients using revyve® over 6–12 weeks Preclinical in vitro studies demonstrated >80% reduction in protease activity, …
Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for its Nectin-4 Targeting ADC CRB-701 at the 2025 ESMO Annual Congress
GlobeNewswire
·
July 30, 2025
NORWOOD, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, announced today that an abstract on updated clinical data from its Phase 1/2 clinical study …
LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
GlobeNewswire
·
July 30, 2025
New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 88-member sales force hired and prepared to initiate sales and marketing activities immediately upon approval Executed multiple …
Spectral AI Schedules 2025 Second Quarter Financial Results and Conference Call
GlobeNewswire
·
July 30, 2025
DALLAS, July 30, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System and focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today …
Immutep Quarterly Activities Report Q4 FY25
GlobeNewswire
·
July 30, 2025
Media Release The pivotal TACTI-004 Phase III trial in first line non-small cell lung cancer (1L NSCLC) continues to build momentum and is recruiting patients at a growing number of activated clinical sites and countries Trial-in-Progress poster for TACTI- …
VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo
GlobeNewswire
·
July 30, 2025
Trial Did Not Meet Primary Endpoint or Key Secondary Endpoint of F-VASI50 and F-VASI75 Nominally Statistically Significant Effects Observed in Key Secondary and Exploratory Endpoints of Change from Baseline in F-VASI and T-VASI at 3% Concentration Company …
Valitor Highlights Three-fold Increase with VLTR-559 in Sustained Potency and Durability over Aflibercept in Preclinical Ocular Wet AMD Models
GlobeNewswire
·
July 30, 2025
-Data showcased in session titled “Spotlight on Drug Delivery” at the Ophthalmology Innovation Source (OIS) Retina 8th Annual Innovation Summit -VLTR-559, a long-acting anti-VEGF therapy, could reduce dosing frequency for the treatment of wet AMD to twice- …
Nautilus Biotechnology Announces Agreement with the Allen Institute, Further Validating its Approach to Single-Molecule Proteomics
GlobeNewswire
·
July 30, 2025
• Allen Institute to employ Iterative Mapping, Nautilus’ single-molecule proteomics method, to investigate connection between tau protein and Alzheimer’s disease • Agreement links the organizations’ next-generation proteomics technology and neuroscience …
Bionano Recaps Momentum behind Optical Genome Mapping at the Biennial Meeting of the European Cytogenomics Association Held Recently in Leuven, Belgium
GlobeNewswire
·
July 30, 2025
SAN DIEGO, July 30, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) recently participated in the European Cytogenomics Conference, which is the biennial meeting of the European Cytogenomics Association (ECA). The conference was held in …
Profusa Announces Initial $1 Million Bitcoin Investment to Initiate Its Digital Asset Treasury Strategy
GlobeNewswire
·
July 30, 2025
BERKELEY, Calif, July 30, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (NASDAQ: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an …
Paragon Genomics and Genecast Announce Global Partnership to Advance Precision Oncology
GlobeNewswire
·
July 30, 2025
FREMONT, Calif. and TAIZHOU, China, July 30, 2025 (GLOBE NEWSWIRE) -- Paragon Genomics, Inc., a global leader in target enrichment solutions for next-generation sequencing (NGS), and Genecast (Taizhou) Biotechnology Co., Ltd., a pioneering oncology …
ORYZON Reports Financial Results and Corporate Update for Half-Year Ending June 30, 2025
GlobeNewswire
·
July 30, 2025
Between December 2024 and July 2025, Oryzon secured financing totaling €52 M, approx. $61 M (€30.0 M from a capital increase, €7.0 M from commercial bank loans, €13.2 M from the EU-IPCEI grant, and €1.8 M from R…
BriaCell Awarded New Zealand Patent for its Whole Cell Technology
GlobeNewswire
·
July 30, 2025
PHILADELPHIA and VANCOUVER, British Columbia, July 30, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to …
Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025
GlobeNewswire
·
July 30, 2025
BOSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, announced today that clinical data …